INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,545,965 | +55.1% | 48,892 | +100.0% | 0.00% | +100.0% |
| Q2 2023 | $996,908 | -10.2% | 24,446 | -17.9% | 0.00% | 0.0% |
| Q1 2023 | $1,109,565 | -35.7% | 29,771 | -39.8% | 0.00% | -50.0% |
| Q4 2022 | $1,725,276 | -31.1% | 49,449 | +9.2% | 0.00% | -33.3% |
| Q3 2022 | $2,503,000 | +7.7% | 45,271 | +0.9% | 0.00% | 0.0% |
| Q2 2022 | $2,323,000 | -37.7% | 44,877 | -12.5% | 0.00% | 0.0% |
| Q1 2022 | $3,728,000 | -45.2% | 51,295 | -10.9% | 0.00% | -50.0% |
| Q4 2021 | $6,805,000 | -7.5% | 57,549 | +5.0% | 0.01% | -25.0% |
| Q3 2021 | $7,355,000 | -7.3% | 54,830 | -2.0% | 0.01% | 0.0% |
| Q2 2021 | $7,934,000 | +92.1% | 55,930 | +8.6% | 0.01% | +60.0% |
| Q1 2021 | $4,131,000 | +64.3% | 51,479 | +11.4% | 0.01% | +66.7% |
| Q4 2020 | $2,515,000 | +225.8% | 46,229 | +19.0% | 0.00% | +200.0% |
| Q3 2020 | $772,000 | +6.3% | 38,857 | +12.4% | 0.00% | 0.0% |
| Q2 2020 | $726,000 | – | 34,557 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |